VNRX Company Profile and Key Details

Short-term trend indicators are bullishly aligned (SMA20 0.3%, SMA50 -9.6%, SMA200 -51.32%). The stock’s 14-day RSI is 48.19 (neutral), while the ATR of 0.03 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -74.84% below its high and over 39.12% above its low. Average 10-day trading volume of 229.25 thousand shares is below the 3-month average of 290.63 thousand, indicating normal recent market interest.

VolitionRX Ltd has 107.59 million shares outstanding. The public float is 77.25 million shares, elevated short interest at 0.38% of float. This equals 298.50 thousand shares. The short ratio is 1.79 days. Institutional investors hold 22.77% of the float. Insiders own 8.62%. Reynolds Cameron John holds 2.55 million shares, Faulkes Martin Charles has 1.67 million shares and Micallef Jacob Vincent has 426.03 thousand shares.

VolitionRX Ltd last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.37. This means the shares are trading below this model’s fair value.

VolitionRX Ltd generated EPS of -$0.23 over the past year. Five-year average earnings growth is 5.38%. The latest quarter delivered EPS of -$0.97. The next quarter is forecast at -$0.04. Next year's EPS is expected at $20.27. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 17 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $5.00 to $1.00. The high target offers 284.62% upside. The low target suggests -23.08% downside. The mean target is $3.76. This offers 189.23% upside. VolitionRX Ltd earnings surprise history is a consistent trend of beating forecasts. The quarter that ended May 14, 2026, missed forecasts by 38.57%. The prior quarter beat by 2400.0%. Over the last six quarters, Apple has recorded several small beats. These include 0.0% in March 31, 2025.

VolitionRX Ltd (AMEX:VNRX) closed at $1.30 USD, losing -$0.05 (-3.70%) from the previous close of $1.35. The stock is currently mid-range between its 52-week high and low $1.17 and $16.00. With a market capitalization of about $10.84 million, VolitionRX Ltd is classified as a micro-cap and shows market-like volatility (beta ~1.11). Key stats such as the average daily volume over the past year has been around 290.69 thousand shares, volume is running light vs its 52-week average. Headquartered in Henderson, NV, VolitionRX Ltd operates in the Healthcare sector and the Medical - Specialties industry. Led by CEO Cameron Reynolds, the company employs approximately 75 people and listed since March 02, 2012. VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia.

VolitionRX Ltd trades at a P/E ratio of -0.3, slightly below the S&P 500 average, with a price-to-sales ratio of 4.36 and a price-to-book ratio of -0.28 indicating negative book value, which may reflect financial stress. The P/FCF stands at -0.52, also above market averages.

Our AI price prediction model suggests that VolitionRX Ltd stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -39.23%, with price expected at $0.79 by July 27, 2026, within a range of $0.32 to $1.23 3-Month Outlook: Projected fall of -45.38%, reaching $0.71 by October 08, 2026, with a range of $0.42 to $1.01. 1-Year Outlook: Projected loss of -94.62%, with price at $0.07 by July 13, 2027, within a range of $0.00 to $0.11.

VolitionRX Ltd (AMEX:VNRX) shares are up 24.37% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows VolitionRX Ltd trading at a premium to the broader market with a P/E of -0.3. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $4.80, suggesting 269.23% upside. Our AI forecast model points to short-term weakness (-39.23% over two weeks), a medium-term fall (-45.38% over three months), and a longer-term loss (-94.62% over one year), with expected trading ranges indicating moderate volatility.